LENZ Therapeutics, Inc. logo LENZ - LENZ Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 4
HOLD 1
SELL 0
STRONG
SELL 0
| PRICE TARGET: $12.00 DETAILS
HIGH: $12.00
LOW: $12.00
MEDIAN: $12.00
CONSENSUS: $12.00
UPSIDE: 58.94%

Stock News

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More

Pre-Market Stock Futures: The futures are trading lower on Tuesday, but another week and another set of new highs for the S&P 500 and the Nasdaq, as AI fever overshadowed Iran's peace counteroffer dismissal on Monday. The stock market opened lower on the rejection of President Trump's peace offering, but buyers once again circled the... Here Are Tuesday's Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe's, Matador Resources, Toast and More

May 12, 2026 03:54 AM • 247wallst.com
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026 Expanded sales force on-track to be fully deployed by the end of Q2 2026 Management to host conference call today, May 11, 2026, at 4:30 p.m. EDT SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the first quarter ended March 31, 2026 and recent corporate highlights.

May 11, 2026 12:05 PM • globenewswire.com
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights.

May 04, 2026 04:00 AM • globenewswire.com
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. Since receiving U.S. Food and Drug Administration (FDA) approval in July 2025, LENZ has moved rapidly to expand global access to VIZZ, with submission of the MAA in the United Kingdom representing the sixth ex-U.S. regulatory submission for VIZZ.

Apr 20, 2026 04:00 AM • globenewswire.com
LENZ Therapeutics: Speculative But Strong Buy

LENZ Therapeutics: Speculative But Strong Buy

LENZ Therapeutics offers a very high-risk but even higher-reward opportunity with Vizz, its aceclidine-based eye drop for presbyopia. I estimate a bit conservative base-case fair value of $25 per share, implying ~200% upside from current levels, driven by US and international partnerships. Key forward driver is Vizz refill rates, with management set to disclose actual refill percentages in H2; side effect fears remain demand headwinds.

Apr 01, 2026 02:26 AM • seekingalpha.com
LENZ Therapeutics (NASDAQ:LENZ) versus Abeona Therapeutics (NASDAQ:ABEO) Critical Comparison

LENZ Therapeutics (NASDAQ:LENZ) versus Abeona Therapeutics (NASDAQ:ABEO) Critical Comparison

Abeona Therapeutics (NASDAQ: ABEO - Get Free Report) and LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Risk and Volatility Abeona Therapeutics has a

Mar 24, 2026 09:10 PM • defenseworld.net
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Launched VIZZ ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals Compelling real-world performance of VIZZ, combined with broad prescriber uptake and encouraging early refill trends, reinforces confidence in its best-in-class profile and establishment of a durable new category Management to host conference call today, March 24, 2026, at 8:30am EDT SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the fourth quarter and full year ended December 31, 2025 and recent corporate highlights. “We are encouraged by the early performance of VIZZ.

Mar 24, 2026 04:00 AM • globenewswire.com
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, March 24, 2026, at 8:30 a.m. EDT to report its fourth quarter and full year 2025 financial results and recent corporate highlights.

Mar 17, 2026 04:00 AM • globenewswire.com
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

MAA submission to the European Medicines Agency represents a key regulatory milestone in LENZ's strategy to expand global access to VIZZ Submission of MAA in Europe results in the fifth ex-U.S. regulatory submission for VIZZ SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review and approval of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. If approved, the EMA's positive opinion would serve as a foundational step toward making VIZZ available to the millions of Europeans living with age-related blurry near vision.

Mar 10, 2026 04:00 AM • globenewswire.com
LENZ Therapeutics to Present at Upcoming Investor Conferences

LENZ Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:

Feb 23, 2026 03:00 AM • globenewswire.com
Calamos Timpani Small Cap Growth Fund Q4 2025 Contributors And Detractors

Calamos Timpani Small Cap Growth Fund Q4 2025 Contributors And Detractors

For the quarter ended December 31, 2025, the fund returned 3.77% (Class I shares at NAV), outperforming the Russell 2000 Growth Index return of 1.22%. Lumentum's stock strength in Q4 2025 was driven by a clean earnings beat and accelerating momentum in AI-related optical demand. Stride's common stock declined -56% for the quarter, dropping significantly after the earnings release, even as the company beat EPS and revenue expectations.

Feb 11, 2026 09:00 PM • seekingalpha.com

Price Targets